AIM ImmunoTech prices $8 million public offering at $4 per share

AIM ImmunoTech Inc. (NYSE American: AIM) announced the pricing of a public offering expected to generate approximately $8 million in gross proceeds before fees and expenses.

The offering consists of 2 million shares of common stock or pre-funded warrants at $4.00 per share, along with Class E and Class F warrants to purchase up to 2 million shares each. Pre-funded warrants are priced at $3.999 each.

Both warrant classes carry an exercise price of $4.00 per share and become exercisable immediately upon issuance. Class E warrants expire five years from the original issuance date, while Class F warrants expire after 18 months.

The company expects the offering to close on or about July 30, 2025, subject to standard closing conditions. Maxim Group LLC serves as sole placement agent for the transaction.

The securities are being offered under a registration statement on Form S-1 that was declared effective by the Securities and Exchange Commission on July 28, 2025.

AIM ImmunoTech develops therapeutics for cancers, immune disorders and viral diseases. The Ocala, Florida-based company's lead product candidate is Ampligen, an investigational drug in clinical trials for various cancers and viral diseases.

You May Also Be Interested In

• EShallGo prices $1.75M registered direct offering at $1 per share
• Keenova doses first patient in Phase 3 hammer toe drug trial
• Edesa Biotech launches public offering of common shares